The estimated Net Worth of Benson Kwan Hung Tsang is at least 195 千$ dollars as of 3 August 2022. Mr. Tsang owns over 10,000 units of Athenex Inc stock worth over 10,514$ and over the last 6 years he sold ATNX stock worth over 0$. In addition, he makes 184,036$ as Independent Director at Athenex Inc.
Sign up
Mr. Tsang ATNX stock SEC Form 4 insiders trading
Benson has made over 3 trades of the Athenex Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of ATNX stock worth 2,000$ on 3 August 2022.
The largest trade he's ever made was exercising 10,000 units of Athenex Inc stock on 3 August 2022 worth over 2,000$. On average, Benson trades about 1,538 units every 67 days since 2018. As of 3 August 2022 he still owns at least 52,572 units of Athenex Inc stock.
You can see the complete history of Mr. Tsang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Benson Tsang biography
Benson Kwan Hung Tsang CPA serves as Independent Director of the Company. Mr. Tsang brings over 30 years of financial and general management experience to Athenex. Mr. Tsang has served as a partner of Hongsen Investment Management Limited, the GP of Hongsen Investment Fund LP since January 1, 2020. From July 2015 to present, through his consulting firm, Benita Consulting Company, he provides financial and operational advisory services to companies in Canada and China. From March 2010 to June 2015, Mr. Tsang served as the Chief Financial Officer of ATA Inc. From July 2006 to February 2009, Mr. Tsang held the role of Chief Financial Officer of WuXi Pharmatech Inc. where he played a crucial role in the company’s successful IPO in 2007. Mr. Tsang was appointed as an independent director of Pharmaron Beijing Co., Ltd. in November 2019. Previously, from November 2011 to March 2013, he served as an independent director of Shangpharma Corp. Mr. Tsang has also held senior positions at PCCW Ltd., Imation Corp., Coopers & Lybrand and D&T. He is a member of the Chartered Professional Accountants of Canada and the Hong Kong Institute of Certified Public Accountants. Mr. Tsang holds a Bachelor of Commerce degree and an MBA from McMaster University in Ontario, Canada.
What is the salary of Benson Tsang?
As the Independent Director of Athenex Inc, the total compensation of Benson Tsang at Athenex Inc is 184,036$. There are 8 executives at Athenex Inc getting paid more, with Johnson Lau having the highest compensation of 4,483,840$.
How old is Benson Tsang?
Benson Tsang is 55, he's been the Independent Director of Athenex Inc since 2018. There are 14 older and 3 younger executives at Athenex Inc. The oldest executive at Athenex Inc is John Vierling, 74, who is the Independent Director.
What's Benson Tsang's mailing address?
Benson's mailing address filed with the SEC is C/O ATHENEX, INC., 1001 MAIN STREET, SUITE 600, BUFFALO, NY, 14203.
Insiders trading at Athenex Inc
Over the last 7 years, insiders at Athenex Inc have traded over 33,215,399$ worth of Athenex Inc stock and bought 5,920,005 units worth 73,651,360$ . The most active insiders traders include Advisors Llcperceptive Life...、Song Yi Zhang、Song Yi Mandra Medical Ltd .... On average, Athenex Inc executives and independent directors trade stock every 12 days with the average trade being worth of 10,843$. The most recent stock trade was executed by Joe Annoni on 22 February 2023, trading 625 units of ATNX stock currently worth 125$.
What does Athenex Inc do?
athenex is a global specialty oncology pharmaceutical company focused on the development and commercialization of next generation therapies for cancer diseases and supportive therapies. the company is dedicated to delivering innovative drugs that can have a life-changing impact on cancer patients. our business includes medical technology innovation centers and a unique manufacturing supply chain across both china and north america. through the connected innovation and manufacturing supply chain presence, we can identify, develop and deliver proprietary medical technology across continents and multiple regulatory environments.
What does Athenex Inc's logo look like?
Complete history of Mr. Tsang stock trades at Athenex Inc
Athenex Inc executives and stock owners
Athenex Inc executives and other stock owners filed with the SEC include:
-
Johnson Lau,
Chief Executive Officer and Chairman of the Board -
Rudolf Kwan,
Chief Medical Officer -
Jeffrey Yordon,
Chief Operating Officer and President, Athenex Pharmaceutical Division -
Randoll Sze,
Chief Financial Officer -
Simon Pedder,
Chief Business and Strategy Officer - Proprietary Products -
Jeffrey M. Yordon,
COO & Pres of Athenex Pharmaceutical Division -
Dr. Rudolf Kwan M.D., M.B., B.S.,
Chief Medical Officer -
Dr. Yiu-Nam Lau M.B.B.S., M.D., F.R.C.P., Ph.D.,
Chairman & CEO -
Benson Tsang,
Independent Director -
Stephanie Davis,
Independent Director -
Kim Campbell,
Lead Independent Director -
Jinn Wu,
Independent Director -
Jordan Kanfer,
Independent Director -
John Vierling,
Independent Director -
Manson Fok,
Director -
Robert Spiegel,
Director -
Daniel Lang,
Senior Director - Corporate Development, President - Axis Therapeutics Limited -
Tim McCarthy,
IR Contact Officer -
William Zuo,
President, China Division -
Dr. Wing-Kai Chan,
Deputy Chief Medical Officer of Orascovery & Src Kinase Platforms -
John W. Matthei,
VP of HR -
Caileigh Dougherty,
Director of Investor Relations -
Michael Smolinski Ph.D.,
Chief Scientific Officer -
Steven J. Adams,
Interim Chief Accounting Officer -
Daniel Lang M.D.,
Sr. Director of Corp. Devel. -
Jacqueline Li,
Director of Corp. Devel. & Investor Relations -
Steven Rubis,
Sr. Director of Investor Relations -
Teresa Brophy Bair,
Gen. Counsel, Sr. VP of Admin. & Corp. Sec. -
Dr. Allen Barnett,
Co-Founder & Pres Emeritus -
James Zukin,
-
Michael D Cannon,
-
J Nick Riehle,
Chief Financial Officer -
Antony Leung,
-
Song Yi Zhang,
Director -
John Koh,
Director -
Advisors Llcperceptive Life...,
-
Sheldon Trainor Degirolamo,
Director -
Timothy De Vere Cook,
See Remarks -
Teresa Brophy Bair,
General Counsel, SVP Admin. -
Joe Annoni,
Chief Financial Officer -
Steven J. Adams,
Interim Chief Acct Officer -
Michael Smolinski,
Chief Scientific Officer